BMEA Biomea Fusion Forecast, Technical & Fundamental Analysis
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases... Show more
BMEA is expected to report earnings to rise 22.71% to -20 cents per share on August 03
Q2'26
Est.
$-0.21
Q1'26
Beat
by $0.06
Q4'25
Beat
by $0.29
Q3'25
Beat
by $0.02
Q2'25
Beat
by $0.03
The last earnings report on May 11 showed earnings per share of -17 cents, beating the estimate of -23 cents. With 627.23K shares outstanding, the current market capitalization sits at 96.52M.
A.I.dvisor indicates that over the last year, BMEA has been loosely correlated with ACET. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if BMEA jumps, then ACET could also see price increases.
BMEA in upward trend: 10-day moving average crossed above 50-day moving average on July 09, 2026
The 10-day moving average for BMEA crossed bullishly above the 50-day moving average on July 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on BMEA as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BMEA just turned positive on June 18, 2026. Looking at past instances where BMEA's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMEA advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 155 cases where BMEA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BMEA moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where BMEA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
BMEA moved below its 50-day moving average on July 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for BMEA moved below the 200-day moving average on June 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
BMEA broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.157) is normal, around the industry mean (22.746). P/E Ratio (0.000) is within average values for comparable stocks, (37.261). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.488). BMEA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (432.117).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMEA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMEA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
